CoChat
Sign Up
Cited by 161

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Gene Therapy for Malignant Glioma: Current Clinical Status

Pulkkanen, Kalevi J., Yla-Herttuala, Seppo·2005·Molecular Therapy
DOI 10.1016/j.ymthe.2005.07.357
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2005.07.357

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 124

  1. Annegers, 1981, Epidemiologic study of primary intracranial neoplasms, Arch. Neurol., 38, 217, 10.1001/archneur.1981.00510040043006 · DOI
  2. Louis, 2001, Glioma classification: a molecular reappraisal, Am. J. Pathol., 159, 779, 10.1016/S0002-9440(10)61750-6 · DOI
  3. Fine, 1993, Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults, Cancer, 71, 2585, 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S · DOI
  4. Castro, 2003, Current and future strategies for the treatment of malignant brain tumors, Pharmacol. Ther., 98, 71, 10.1016/S0163-7258(03)00014-7 · DOI
  5. Levin, 1985, Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas, J. Neurosurg., 63, 218, 10.3171/jns.1985.63.2.0218 · DOI
  6. Levin, 1995, Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas, Int. J. Radiat. Oncol. Biol. Phys., 32, 75, 10.1016/0360-3016(94)00488-7 · DOI
  7. Immonen, 2004, AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study, Mol. Ther., 10, 967, 10.1016/j.ymthe.2004.08.002 · DOI
  8. Pulkkanen, 2004, Cancer gene therapy—Current status in the clinics, Gene Ther. Regul., 2, 219, 10.1163/1568558042457488 · DOI
  9. Alemany, 2000, Replicative adenoviruses for cancer therapy, Nat. Biotechnol., 18, 723, 10.1038/77283 · DOI
  10. Kirn, 2001, Replication-selective virotherapy for cancer: biological principles, risk management and future directions, Nat. Med., 7, 781, 10.1038/89901 · DOI
  11. Banerjee, 2002, Myeloprotection with drug-resistance genes, Lancet Oncol., 3, 154, 10.1016/S1470-2045(02)00678-2 · DOI
  12. Lowenstein, 2002, Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective, Trends Immunol., 23, 23, 10.1016/S1471-4906(01)02063-4 · DOI
  13. Aghi, 2000, Prodrug activation enzymes in cancer gene therapy, J. Gene Med., 2, 148, 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q · DOI
  14. Shah, 2003, Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas, J. Neurooncol., 65, 203, 10.1023/B:NEON.0000003651.97832.6c · DOI
  15. Carmeliet, 2000, Angiogenesis in cancer and other diseases, Nature, 407, 249, 10.1038/35025220 · DOI · Paper page
  16. Taniguchi, 1998, Targeting angiogenesis: genetic intervention which strikes at the weak link of tumorigenesis, Gene Ther., 5, 1011, 10.1038/sj.gt.3300749 · DOI
  17. Matsuno, 2004, Specific gene suppression using antisense strategy for growth suppression of glioma, Med. Electron Microsc., 37, 158, 10.1007/s00795-004-0251-6 · DOI
  18. Andrews, 2001, Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas, J. Clin. Oncol., 19, 2189, 10.1200/JCO.2001.19.8.2189 · DOI
  19. Jansen, 2004, Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas, Brain Res. Brain Res. Rev., 45, 143, 10.1016/j.brainresrev.2004.03.001 · DOI
  20. Nakamizo, 2005, Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas, Cancer Res., 65, 3307, 10.1158/0008-5472.CAN-04-1874 · DOI
  21. Shah, 2005, Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression, Ann. Neurol., 57, 34, 10.1002/ana.20306 · DOI
  22. Rainov, 2003, Clinical trials with retrovirus mediated gene therapy—What have we learned?, J. Neurooncol., 65, 227, 10.1023/B:NEON.0000003652.71665.f2 · DOI
  23. Kay, 2001, Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics, Nat. Med., 7, 33, 10.1038/83324 · DOI
  24. Sandmair, 2000, Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses, Hum. Gene Ther., 11, 2197, 10.1089/104303400750035726 · DOI
  25. Danthinne, 2000, Production of first generation adenovirus vectors: a review, Gene Ther., 7, 1707, 10.1038/sj.gt.3301301 · DOI
  26. Romano, 2000, Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications, Stem Cells, 18, 19, 10.1634/stemcells.18-1-19 · DOI
  27. Kanerva, 2004, Modified adenoviruses for cancer gene therapy, Int. J. Cancer, 110, 475, 10.1002/ijc.20129 · DOI
  28. Varghese, 2002, Oncolytic herpes simplex virus vectors for cancer virotherapy, Cancer Gene Ther., 9, 967, 10.1038/sj.cgt.7700537 · DOI
  29. Mizuno, 1998, Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration, Jpn. J. Cancer Res., 89, 76, 10.1111/j.1349-7006.1998.tb00482.x · DOI
  30. Wilcox, 2001, Reovirus as an oncolytic agent against experimental human malignant gliomas, J. Natl. Cancer Inst., 93, 903, 10.1093/jnci/93.12.903 · DOI
  31. Russell, 2002, RNA viruses as virotherapy agents, Cancer Gene Ther., 9, 961, 10.1038/sj.cgt.7700535 · DOI
  32. Csatary, 1999, Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma, JAMA, 281, 1588, 10.1001/jama.281.17.1588-a · DOI
  33. Ren, 2003, Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki Forest virus vector carrying the human interleukin-12 gene—a phase I/II clinical protocol, J. Neurooncol., 64, 147, 10.1007/BF02700029 · DOI
  34. Gridley, 1998, Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy, Int. J. Oncol., 13, 1093
  35. Timiryasova, 1999, Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis, Int. J. Oncol., 14, 845
  36. Gromeier, 2000, Intergeneric poliovirus recombinants for the treatment of malignant glioma, Proc. Natl. Acad. Sci. USA, 97, 6803, 10.1073/pnas.97.12.6803 · DOI
  37. Jackson, 2001, Repetitive intrathecal injections of poliovirus replicons result in gene expression in neurons of the central nervous system without pathogenesis, Hum. Gene Ther., 12, 1827, 10.1089/104303401753153893 · DOI
  38. Naldini, 1996, Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector, Proc. Natl. Acad. Sci. USA, 93, 11382, 10.1073/pnas.93.21.11382 · DOI · Paper page
  39. Stein, 2002, Gene transfer to the brain using feline immunodeficiency virus-based lentivirus vectors, Methods Enzymol., 346, 433, 10.1016/S0076-6879(02)46070-3 · DOI
  40. Thomas, 2003, Non-viral gene therapy: polycation-mediated DNA delivery, Appl. Microbiol. Biotechnol., 62, 27, 10.1007/s00253-003-1321-8 · DOI
  41. Niidome, 2002, Gene therapy progress and prospects: nonviral vectors, Gene Ther., 9, 1647, 10.1038/sj.gt.3301923 · DOI
  42. Schatzlein, 2001, Non-viral vectors in cancer gene therapy: principles and progress, Anticancer Drugs, 12, 275, 10.1097/00001813-200104000-00001 · DOI
  43. Yoshida, 2001, Rat glioma cell death induced by cationic liposome-mediated transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment, J. Surg. Oncol., 76, 19, 10.1002/1096-9098(200101)76:1<19::AID-JSO1004>3.0.CO;2-D · DOI
  44. Yoshida, 2003, Clinical gene therapy for brain tumors: liposomal delivery of anticancer molecule to glioma, J. Neurooncol., 65, 261, 10.1023/B:NEON.0000003655.03671.fa · DOI
  45. Oldfield, 1993, Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir, Hum. Gene Ther., 4, 39, 10.1089/hum.1993.4.1-39 · DOI
  46. Raffel, 1994, Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system, Hum. Gene Ther., 5, 863, 10.1089/hum.1994.5.7-863 · DOI
  47. Kun, 1995, Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors, Hum. Gene Ther., 6, 1231, 10.1089/hum.1995.6.9-1231 · DOI
  48. Freeman, 1993, The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified, Cancer Res., 53, 5274
  49. Mesnil, 1996, Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins, Proc. Natl. Acad. Sci. USA, 93, 1831, 10.1073/pnas.93.5.1831 · DOI
  50. Ram, 1997, Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells, Nat. Med., 3, 1354, 10.1038/nm1297-1354 · DOI
  51. Klatzmann, 1998, A phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma, Hum. Gene Ther., 9, 2595, 10.1089/hum.1998.9.17-2595 · DOI
  52. Shand, 1999, A phase 1–2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European–Canadian Study Group, Hum. Gene Ther., 10, 2325, 10.1089/10430349950016979 · DOI
  53. Valery, 2002, Long-term survival after gene therapy for a recurrent glioblastoma, Neurology, 58, 1109, 10.1212/WNL.58.7.1109 · DOI
  54. Izquierdo, 1996, Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy, Gene Ther., 3, 491
  55. Izquierdo, 1997, Gene therapy in brain tumours: implications of the size of glioblastoma on its curability, Acta Neurochir. Suppl., 68, 111, 10.1007/978-3-7091-6513-3_21 · DOI
  56. Packer, 2000, Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration, J. Neurosurg., 92, 249, 10.3171/jns.2000.92.2.0249 · DOI
  57. Palu, 1999, Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans, Gene Ther., 6, 330, 10.1038/sj.gt.3300805 · DOI
  58. Prados, 2003, Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial, J. Neurooncol., 65, 269, 10.1023/B:NEON.0000003588.18644.9c · DOI
  59. Puumalainen, 1998, Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses, Hum. Gene Ther., 9, 1769, 10.1089/hum.1998.9.12-1769 · DOI
  60. Harsh, 2000, Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study, J. Neurosurg., 92, 804, 10.3171/jns.2000.92.5.0804 · DOI
  61. Rainov, 2000, A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme, Hum. Gene Ther., 11, 2389, 10.1089/104303400750038499 · DOI
  62. Eck, 1996, Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial, Hum. Gene Ther., 7, 1465, 10.1089/hum.1996.7.12-1465 · DOI
  63. Trask, 2000, Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors, Mol. Ther., 1, 195, 10.1006/mthe.2000.0030 · DOI
  64. Germano, 2003, Adenovirus/herpes simplex–thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas, J. Neurooncol., 65, 279, 10.1023/B:NEON.0000003657.95085.56 · DOI
  65. Smitt, 2003, Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir, Mol. Ther., 7, 851, 10.1016/S1525-0016(03)00100-X · DOI
  66. Jacobs, 2001, Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas, Lancet, 358, 727, 10.1016/S0140-6736(01)05904-9 · DOI
  67. Voges, 2002, Liposomal gene therapy with the herpes simplex thymidine kinase gene/ganciclovir system for the treatment of glioblastoma multiforme, Hum. Gene Ther., 13, 675, 10.1089/10430340252837260 · DOI
  68. Hunter, 1999, Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates, J. Virol., 73, 6319, 10.1128/JVI.73.8.6319-6326.1999 · DOI
  69. Sundaresan, 2000, Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice, J. Virol., 74, 3832, 10.1128/JVI.74.8.3832-3841.2000 · DOI
  70. Mineta, 1995, Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas, Nat. Med., 1, 938, 10.1038/nm0995-938 · DOI
  71. Markert, 2000, Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial, Gene Ther., 7, 867, 10.1038/sj.gt.3301205 · DOI
  72. McKie, 1998, Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy, Neuropathol. Appl. Neurobiol., 24, 367, 10.1046/j.1365-2990.1998.00133.x · DOI
  73. Rampling, 2000, Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma, Gene Ther., 7, 859, 10.1038/sj.gt.3301184 · DOI
  74. Papanastassiou, 2002, The potential for efficacy of the modified (ICP 34.5(−)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study, Gene Ther., 9, 398, 10.1038/sj.gt.3301664 · DOI
  75. Harland, 2002, HSV1716 persistence in primary human glioma cells in vitro, Gene Ther., 9, 1194, 10.1038/sj.gt.3301782 · DOI
  76. Harrow, 2004, HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival, Gene Ther., 11, 1648, 10.1038/sj.gt.3302289 · DOI
  77. Lamont, 2000, A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience), Ann. Surg. Oncol., 7, 588, 10.1007/BF02725338 · DOI
  78. Khuri, 2000, A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer, Nat. Med., 6, 879, 10.1038/78638 · DOI
  79. Nemunaitis, 2001, Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer, J. Clin. Oncol., 19, 289, 10.1200/JCO.2001.19.2.289 · DOI
  80. Reid, 2002, Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints, Cancer Res., 62, 6070
  81. Hamid, 2003, Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer, J. Clin. Oncol., 21, 1498, 10.1200/JCO.2003.09.114 · DOI
  82. Makower, 2003, Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies, Clin. Cancer Res., 9, 693
  83. Chiocca, 2004, A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting, Mol. Ther., 10, 958, 10.1016/j.ymthe.2004.07.021 · DOI
  84. Bogler, 1995, The p53 gene and its role in human brain tumors, Glia, 15, 308, 10.1002/glia.440150311 · DOI
  85. Li, 1999, Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma, Clin. Cancer Res., 5, 637
  86. Lang, 1999, Adenovirus-mediated p53 gene therapy for human gliomas, Neurosurgery, 45, 1093, 10.1097/00006123-199911000-00016 · DOI
  87. Lang, 2003, Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results, J. Clin. Oncol., 21, 2508, 10.1200/JCO.2003.11.138 · DOI
  88. Natsume, 1999, Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse, Gene Ther., 6, 1626, 10.1038/sj.gt.3300990 · DOI
  89. Natsume, 2000, IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma, J. Neurooncol., 47, 117, 10.1023/A:1006441030976 · DOI
  90. Yoshida, 2004, Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes, Hum. Gene Ther., 15, 77, 10.1089/10430340460732472 · DOI
  91. Okada, 2000, Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response, Hum. Gene Ther., 11, 637, 10.1089/10430340050015824 · DOI
  92. Eck, 2001, Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial, Hum. Gene Ther., 12, 97, 10.1089/104303401451013 · DOI
  93. Okada, 2001, Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response, Hum. Gene Ther., 12, 575, 10.1089/104303401300042528 · DOI
  94. Resnicoff, 1996, Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA, J. Exp. Ther. Oncol., 1, 385
  95. Barba, 1994, Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors, Proc. Natl. Acad. Sci. USA, 91, 4348, 10.1073/pnas.91.10.4348 · DOI
  96. Long, 1999, Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy, Hum. Gene Ther., 10, 733, 10.1089/10430349950018490 · DOI
  97. Rainov, 1996, Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm, Cancer Gene Ther., 3, 99
  98. Russell, 1995, The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines, Hum. Gene Ther., 6, 635, 10.1089/hum.1995.6.5-635 · DOI
  99. Inamura, 1994, Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors, J. Neurosurg., 81, 752, 10.3171/jns.1994.81.5.0752 · DOI
  100. LeMay, 1998, Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy, Hum. Gene Ther., 9, 989, 10.1089/hum.1998.9.7-989 · DOI
  101. Freije, 2004, Gene expression profiling of gliomas strongly predicts survival, Cancer Res., 64, 6503, 10.1158/0008-5472.CAN-04-0452 · DOI
  102. Nunes, 1999, Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration, Hum. Gene Ther., 10, 2515, 10.1089/10430349950016852 · DOI
  103. Raper, 2003, Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol. Genet. Metab., 80, 148, 10.1016/j.ymgme.2003.08.016 · DOI
  104. Wood, 1994, Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors, Gene Ther., 1, 283
  105. Byrnes, 1995, Adenovirus gene transfer causes inflammation in the brain, Neuroscience, 66, 1015, 10.1016/0306-4522(95)00068-T · DOI
  106. Thomas, 2000, Proc. Natl. Acad. Sci. USA, 97, 7482, 10.1073/pnas.120474397 · DOI
  107. Dewey, 1999, Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials, Nat. Med., 5, 1256, 10.1038/15207 · DOI
  108. Zermansky, 2001, Towards global and long-term neurological gene therapy: unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS, Mol. Ther., 4, 490, 10.1006/mthe.2001.0479 · DOI
  109. Vile, 2000, Cancer gene therapy: hard lessons and new courses, Gene Ther., 7, 2, 10.1038/sj.gt.3301084 · DOI
  110. Bessis, 2004, Immune responses to gene therapy vectors: influence on vector function and effector mechanisms, Gene Ther., 11, S10, 10.1038/sj.gt.3302364 · DOI
  111. Wakimoto, 2003, Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells, Gene Ther., 10, 983, 10.1038/sj.gt.3302038 · DOI
  112. Thomas, 2001, Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors, Hum. Gene Ther., 12, 839, 10.1089/104303401750148829 · DOI
  113. Zou, 2000, Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system, Mol. Ther., 2, 105, 10.1006/mthe.2000.0104 · DOI
  114. Yip, 2003, Neural stem cell biology may be well suited for improving brain tumor therapies, Cancer J., 9, 189, 10.1097/00130404-200305000-00007 · DOI
  115. Grana, 2002, Pretargeted adjuvant radioimmunotherapy with yttrium-90–biotin in malignant glioma patients: a pilot study, Br. J. Cancer, 86, 207, 10.1038/sj.bjc.6600047 · DOI
  116. Lehtolainen, 2003, Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor–avidin fusion protein, Gene Ther., 10, 2090, 10.1038/sj.gt.3302120 · DOI
  117. Qian, 2002, Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway, Pharmacol. Rev., 54, 561, 10.1124/pr.54.4.561 · DOI
  118. Nanda, 2001, Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase, Cancer Res., 61, 8743
  119. Ali, 2004, Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression, Mol. Ther., 10, 1071, 10.1016/j.ymthe.2004.08.025 · DOI
  120. Boviatsis, 1994, Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene, Cancer Res., 54, 5745
  121. Chase, 1998, An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy, Nat. Biotechnol., 16, 444, 10.1038/nbt0598-444 · DOI
  122. Blasberg, 1999, Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy, Q. J. Nucl. Med., 43, 163
  123. Gambhir, 2000, Imaging transgene expression with radionuclide imaging technologies, Neoplasia, 2, 118, 10.1038/sj.neo.7900083 · DOI
  124. Nyberg-Hoffman, 1997, Sensitivity and reproducibility in adenoviral infectious titer determination, Nat. Med., 3, 808, 10.1038/nm0797-808 · DOI

Cited by

Sorted by citations

See all 161

Metadata

Authors
Pulkkanen, K. J., & Yla-Herttuala, S.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2005-10
Volume
12
Issue
4
Pages
585-598
ISSN
1525-0016
DOI
10.1016/j.ymthe.2005.07.357
Cited by
161
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review